Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00286988
Recruitment Status : Terminated (Insufficient potential subjects)
First Posted : February 6, 2006
Last Update Posted : January 6, 2011
Ortho-McNeil Neurologics, Inc.
Information provided by:
Monarch Medical Research

Brief Summary:
The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome.

Condition or disease Intervention/treatment Phase
Vomiting Drug: Topiramate Phase 4

Detailed Description:

There is very little controlled data on the preventative treatment for Cyclic Vomiting Syndrome. The existing evidence consists of small, retrospective clinical series that evaluate symptomatic responses to five medications including cyproheptadine, propranolol, amitriptyline, phenobarbital and pizotifen (n >10). These published data consist of uncontrolled or retrospective reports. In addition, varying inclusion criteria and outcomes (i.e. obtained by family recall) were used in these studies limiting the basis upon which to compare relative effectiveness.

During the prospective baseline period, the subject will maintain cyclical vomiting records in which all headache occurrences will be recorded and characterized. (Cyclical vomiting records will be maintained throughout the study). The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome using a prospective design, established diagnostic criteria (ICHD 2004), and defined, objective primary and secondary endpoints.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children
Study Start Date : March 2006
Actual Primary Completion Date : May 2007
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Topiramate

Primary Outcome Measures :
  1. Reduction of cycle frequency as measured by number of days between cycles.

Secondary Outcome Measures :
  1. Decreased duration of attacks (measured in hours)
  2. Decreased intensity of attacks (0-4 point scale; none, mild, moderate, severe, excruciating)
  3. Decreased associated symptoms (0-4 point scales; none, mild, moderate, severe, excruciating)
  4. Nausea
  5. Vomiting
  6. Headache
  7. Abdominal pain
  8. Decreased disability
  9. PedMidas
  10. Missed school (days per attack)
  11. Missed work (parent(s)) (days per attack)
  12. Decreased use of acute therapies (e.g. anti-emetics)
  13. Decreased emergency department visits.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meet the2004 ICHD Criteria for Cyclical Vomiting.

    • 1 vomiting attack lasting > 24 hours duration for 3 consecutive months
  • 4-12 years of age.
  • If female, subjects must:

    1. be premenarchal or otherwise incapable of pregnancy, or
    2. have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility, or
    3. be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence.
  • Able to take oral medication in tablet form or sprinkle form
  • Subjects or their guardians must be willing and able to: a) read and comprehend written instructions, b) complete the assessment forms, c) return for regular visits, and d) adhere to medication regimens.
  • Subjects (or their legally acceptable representative) must have signed an informed consent document

Exclusion Criteria

  • Have taken topiramate within 14 days prior to the start of the prospective baseline period.
  • Have taken certain medications for cyclical vomiting prophylaxis
  • Have progressive neurological disorder or a structural disorder of the brain from birth, trauma or past infection.
  • Subjects who have taken any medications for migraine prophylaxis, within 2 weeks of the start of the prospective baseline period.
  • Subjects starting non-pharmacologic prophylactic approaches (e.g., acupuncture, biofeedback, chiropractic methods) within 1 month prior to Visit 1.
  • Require continuing treatment with anticonvulsant therapy for a non-migraine condition.
  • Significant major psychiatric disorder (e.g., major depression) or subjects receiving anti-psychotic medication.
  • History of attempted suicide or suicidal tendencies.
  • History of substance abuse.
  • Pregnant or lactating females.
  • Have clinically unstable neurological, cardiovascular, gastrointestinal, musculoskeletal, pulmonary or other disease.
  • Have any disease or condition that could compromise the function of those body systems that could result in altered absorption, excess accumulation, or impaired metabolism or excretion of the test medications (e.g., abnormal renal and/or hepatic function).
  • Have active liver disease.
  • Have received an investigational drug or used an investigational device within 30 days of study entry.
  • Employees of the investigator, study center, or sponsor (i.e., principal investigator, sub-investigator(s), study coordinators, other study staff, employees, or contractors of each), with direct involvement in the proposed study or other studies under the direction of that investigator, study center or sponsor, as well as family members of the employees or the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00286988

Layout table for location information
United States, Virginia
Monarch Medical Research - Child and Adolescent Neurology
Norfolk, Virginia, United States, 23510
Sponsors and Collaborators
Monarch Medical Research
Ortho-McNeil Neurologics, Inc.
Layout table for investigator information
Principal Investigator: Donald W Lewis, MD Monarch Medical Research
Additional Information:
Layout table for additonal information
Responsible Party: Donald W Lewis, MD, Children's Specialty Group Identifier: NCT00286988    
Other Study ID Numbers: TOPMAT-EME-4001
First Posted: February 6, 2006    Key Record Dates
Last Update Posted: January 6, 2011
Last Verified: April 2007
Keywords provided by Monarch Medical Research:
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Hypoglycemic Agents
Physiological Effects of Drugs